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ABSTRACT
Objectives To investigate the validity and feasibility of
the Juvenile Arthritis Disease Activity Score ( JADAS) in
the routine clinical setting for all juvenile idiopathic
arthritis ( JIA) disease categories and explore whether
exclusion of the erythrocyte sedimentation rate (ESR)
from JADAS (the ‘JADAS3’) inﬂuences correlation with
single markers of disease activity.
Methods JADAS-71, JADAS-27 and JADAS-10 were
determined at baseline for an inception cohort of children
with JIA in the Childhood Arthritis Prospective Study.
JADAS3-71, JADAS3-27 and JADAS3-10 were determined
using an identical formula but with exclusion of ESR.
Correlation of JADAS with JADAS3 and single measures of
disease activity/severity were determined by category.
Results Of 956 eligible children, sufﬁcient data were
available to calculate JADAS-71, JADAS-27 and JADAS-10
at baseline in 352 (37%) and JADAS3 in 551 (58%). The
median (IQR) JADAS-71, JADAS-27 and JADAS-10 for all
352 children was 11 (5.9–18), 10.4 (5.7–17) and 11
(5.9–17.3), respectively. Median JADAS and JADAS3
varied signiﬁcantly with the category (Kruskal–Wallis
p=0.0001), with the highest values in children with
polyarticular disease patterns. Correlation of JADAS and
JADAS3 across all categories was excellent. Correlation of
JADAS71 with single markers of disease activity/severity
was good to moderate, with some variation across the
categories. With the exception of ESR, correlation of
JADAS3-71 was similar to correlation of JADAS-71 with
the same indices.
Conclusions This study is the ﬁrst to apply JADAS to all
categories of JIA in a routine clinical setting in the UK,
adding further information about the feasibility and
construct validity of JADAS. For the majority of categories,
clinical applicability would be improved by exclusion of the
ESR.
INTRODUCTION
Inﬂammatory arthritis, one of the most common
chronic illnesses of childhood, occurs in approxi-
mately 10 : 100 000 children each year,1 with the
majority subsequently diagnosed with juvenile idio-
pathic arthritis ( JIA). JIA is an umbrella term, sum-
marising the internationally recognised International
League Against Rheumatism (ILAR) classiﬁcation
system for the markedly heterogeneous chronic
paediatric arthritides.2 3
The term ‘disease activity’ refers to the overall
burden of inﬂammatory disease at a particular
point in time. Accurate assessment of disease activ-
ity is central to improving clinical outcomes in JIA,
since the prevention of joint damage and associated
long-term disability requires prompt recognition
and control of inﬂammatory disease. The heteroge-
neous nature of JIA ensures that no single measure
can reliably capture overall disease activity in all
patients. A feasible, valid and reproducible assess-
ment of disease activity is integral to the design of
new clinical studies and clinical trials, improving
the efﬁciency and effectiveness of clinical research
and enabling between-study comparisons.
The Juvenile Arthritis Disease Activity Score
( JADAS) is a new composite disease activity score
speciﬁc to JIA.4 It is simple to calculate using four
variables measured in the clinical setting: active
joint count (AJC), physician global assessment
(physician global), parent global evaluation (parent
global) and erythrocyte sedimentation rate (ESR).
JADAS has been shown to be feasible, with good
construct validity, discriminant validity and respon-
siveness to clinically important change.4 However,
many of the original validation data were derived
from clinical trials, with a predominance of
polyarticular-course disease and very few children
with enthesitis-related or psoriatic JIA. An observa-
tional study of JADAS was published in 2012, but,
despite a relatively large sample size, the validity
and feasibility of JADAS was difﬁcult to ascertain
in all ILAR categories because of the relative infre-
quency of some of the categories in the popula-
tion.5 Furthermore, it is recognised that the ESR is
not routinely measured in all clinical settings,
largely because of the stress and difﬁculty asso-
ciated with regular blood testing. The ESR is more
likely to be measured in children on medication
requiring blood monitoring, meaning that children
with persistent oligoarticular JIA (the most
common category) are less likely to have an ESR
available than children with systemic onset JIA or a
polyarticular disease pattern. Therefore the JADAS
as proposed, which includes the ESR, is less likely
to be a measure with clinical feasibility and
applicability.
The objectives of this analysis were to (1) investi-
gate the validity and clinical feasibility of JADAS as
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a summary of disease activity at the time of ﬁrst presentation
using data collected in the routine clinical setting in all ILAR
categories of JIA and (2) explore whether exclusion of the ESR
from JADAS (the ‘JADAS3’) inﬂuences correlation with single
markers of disease activity.
METHODS
Study population
Children in this analysis were participants in the Childhood
Arthritis Prospective Study (CAPS), an ongoing prospective
inception cohort study launched in 2001.6 7 CAPS aims to
provide long-term outcome data on children with new-onset
inﬂammatory arthritis receiving routine specialist care in the
UK. In brief, children aged <16 years with a new diagnosis of
inﬂammatory arthritis present for at least 2 weeks, presenting to
one of ﬁve UK paediatric rheumatology centres (Liverpool,
Manchester, Newcastle, Glasgow and Great Ormond Street), are
invited to participate. Exclusion criteria are septic arthritis and
arthritis related to malignancy, trauma or connective tissue
disease (systemic lupus erythematosus, juvenile dermatomyositis
or mixed connective tissue disease). The study was approved by
the UK Northwest Multicentre Research Ethics Committee.
Written informed consent has been obtained from the parent(s)/
guardians of all participating children, and all able children have
provided written assent.
Data collection
Data for this analysis have been collated from the CAPS data-
base and include information from medical records and inter-
view with the child/family. The AJC, limited joint count (LJC)
and 10 cm physician global visual analogue scale (VAS) are
documented by the paediatric rheumatologist at the ﬁrst (base-
line) paediatric rheumatology visit (baseline study visit). The
rheumatologist is asked to assign a predicted ILAR category if
the suspected/conﬁrmed diagnosis is JIA, where possible. For
children presenting within the ﬁrst 6 months of the disease, this
was considered a ‘predicted’ category only. The parent/child is
asked to complete a Childhood Health Assessment
Questionnaire (CHAQ) validated for use in the UK population,8
including a 10 cm parent global VAS and 10 cm pain VAS. A
paediatric rheumatology research nurse interviews the parent(s)
and child within 3 months of the initial visit and extracts demo-
graphic and clinical data from the medical records. Similar data
are collected at 6 months and then annually to 5 years, includ-
ing a conﬁrmation of the underlying diagnosis and ILAR
subtype.
Analysis
All children with a conﬁrmed physician’s diagnosis of JIA were
included in this analysis. For children whose baseline study visit
was within the ﬁrst 6 weeks of disease onset, only those with
further study follow-up conﬁrming a diagnosis of JIA were
included. JADAS-71, JADAS-27 and JADAS-10 were determined
for all children at the time of ﬁrst presentation using the
formula published by Consolaro et al.4
The JADAS is the linear sum of the scores of its four compo-
nents (range=0–101 for JADAS-71, 0–57 for JADAS-27, and 0–
40 for JADAS-10):
JADAS ¼AJCð71;27 or 10 jointsÞ þ physician global ð10cmVASÞ
þ parent global ð10cmVASÞ þ ESR
JADAS-71 includes a complete joint count (71 joints), whereas
JADAS-27 and JADAS-10 include reduced joint counts
( JADAS-27: 27 joints including cervical spine, elbows, wrists,
1st–3rd metacarpophalangeals, proximal interphalangeals, hips,
knees and ankles; JADAS-10: any involved joint to a maximum
of 10). There is no weighting of joints. To avoid excessive
weight in the overall index, the ESR is converted into a 0–10
scale as follows: (ESR (mm/h)−20)/10. ESR values <20 are allo-
cated a score of 0, and ESR results >120 score 10 on the scale.
As the ESR may not have been measured on the same day as the
rheumatology examination, we allowed a window of up to
30 days before or after the ﬁrst visit.
Calculation of the JADAS3 was identical with that for the full
JADAS with the exclusion of ESR (range=0–91 for JADAS3-71,
0–47 for JADAS3-27, and 0–30 for JADAS3-10). To study the
construct validity of JADAS, the correlation of JADAS-71,
JADAS-27 and JADAS-10 with one another and with single
measures of disease activity and severity (AJC, LJC, physician
global, parent global, ESR, pain score and CHAQ) were deter-
mined for the entire cohort and within each ILAR category at
baseline. Although the ILAR category can change with time,9
this study used the ILAR category allocated at baseline to correl-
ate with the timing of recording the components of the JADAS.
All correlations were calculated using Spearman’s rank statistic.
Correlations were considered high, moderate or low at >0.7,
0.4–0.7 and <0.4, respectively. A similar analysis was carried
out for JADAS3, limited at ﬁrst to children with the four-
variable JADAS available and then repeated in the larger cohort
with sufﬁcient data to calculate JADAS3. All analyses were per-
formed using Stata V.10.0.
RESULTS
Baseline characteristics and availability of JADAS
In January 2012, a total of 956 children with a conﬁrmed diag-
nosis of JIA and ILAR category available at baseline had been
recruited to CAPS. The median age at disease onset was
6.6 years (IQR 2.6–10.6), median disease duration at diagnosis
was 5.5 months (IQR 2.9–11.8), and 65% were female
(table 1).
It was not possible to calculate JADAS at the time of ﬁrst
presentation for all children (table 1), with complete data in all
four components being available in just 352/956 children at
baseline (37%). All children had an AJC documented, but 17%
were missing the physician global, 32% missing the parent
global, and 36% missing the ESR (table 2). The ESR had the
widest range of missing data across all ILAR categories
(recorded in 82% of children with systemic onset, 59% with oli-
goarticular and 44% with enthesitis-related JIA). Exclusion of
the ESR from JADAS allowed calculation of JADAS3 in 551/
956 children (58%).
Children with sufﬁcient data available to calculate JADAS-71,
JADAS-27 and JADAS-10 had signiﬁcantly higher LJC and phys-
ician global scores (Kruskal–Wallis p<0.05) than those without,
and there was a trend towards higher pain and CHAQ scores in
this subgroup (table 1). Children with sufﬁcient data to calculate
JADAS3-71, JADAS3-27 and JADAS3-10 had signiﬁcantly
higher physician global scores than the remainder of the cohort.
There was a trend towards a higher proportion of the cohort
with JADAS available having systemic onset JIA, but this did not
reach statistical signiﬁcance (χ2 p=0.12). There was no signiﬁ-
cant difference in ILAR subtype distribution in the cohorts with
and without JADAS3 available (χ2 p=0.2).
JADAS and JADAS3 results by ILAR subtype of JIA
The correlation of JADAS and JADAS3 across all ILAR categor-
ies was excellent (table 3).
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The median (IQR) JADAS-71, JADAS-27 and JADAS-10 for all
352 children was 11 (IQR 5.9–18), 10.4 (5.7–17) and 11 (5.9–
17.3), respectively (table 4). Correlation between the three JADAS
results was high, ranging from 0.87–1.0 across the categories (see
online supplementary table S1). As expected, median JADAS3-71,
JADAS3-27 and JADAS3-10 results were lower than median
JADAS-71, JADAS-27 and JADAS-10, with the greatest difference
in the systemic onset category (table 4). The JADAS and JADAS3
results were minimally different in the extended oligoarticular and
rheumatoid factor (RF)+ polyarticular categories.
Median JADAS and JADAS3 results varied signiﬁcantly with
the ILAR category (Kruskal–Wallis p=0.0001) (table 4 and see
online supplementary table S2).
Construct validity of JADAS and JADAS3 in routine clinical
practice
Correlations of JADAS-71 and JADAS3-71 with individual sur-
rogates for disease activity are presented in table 5. Correlation
of JADAS-71 with AJC was high, with the exception of
persistent oligoarticular JIA (r=0.47). Correlation with the
remaining three variables included within the score varied
across the categories. On average, correlation with the ESR was
the lowest, ranging from low to moderate across the categories.
Correlation of JADAS-71 with other markers of disease activity/
severity, including LJC, CHAQ and pain, ranged from low to
high/moderate across the categories. Low numbers rendered cor-
relation coefﬁcients difﬁcult to interpret in the extended oli-
goarticular and RF+ polyarticular categories.
With the exception of the ESR, correlation of JADAS3-71
with individual measures of disease activity was very similar to
correlation of JADAS-71 with the same indices. Correlation of
JADAS3-71 with the ESR was low in all categories with the
exception of undifferentiated JIA.
As the cohort of children with JADAS available was slightly
weighted towards those with more severe disease, we also
undertook further validation of JADAS3 in all children with
available data (n=551) (see online supplementary table S2).
Compared with the cohort with the full JADAS available, the
Table 1 Baseline characteristics of children with and without available items for the Juvenile Arthritis Disease Activity Score ( JADAS)
Covariate Whole cohort Cohort with JADAS Cohort without JADAS p Value Cohort with JADAS3 Cohort without JADAS3 p Value
N 956 352 604 551 405
Age at onset (years) 6.6 (2.6–10.6) 6.7 (2.7–10.8) 6.4 (2.6–10.6) 0.49 6.6 (2.7–10.6) 6.4 (2.5–10.6) 0.82
Female (%) 65 66 64 0.54 64 65 0.75
Caucasian (%) 90 91 90 0.73 91 90 0.45
Disease duration (months) 5.5 (2.9–11.8) 5.5 (2.7–11.8) 5.5 (2.9–12.1) 0.60 5.6 (2.8–12.6) 5.4 (2.9–10.6) 0.51
ILAR category
Systemic 57 (6) 28 (8) 29 (5) 0.12 31 (6) 26 (6) 0.2
Persistent oligoarthritis 484 (51) 164 (47) 320 (53) 274 (50) 210 (52)
Extended oligoarthritis 23 (2) 13 (4) 10 (2) 18 (3) 5 (1)
RF− polyarthritis 175 (18) 67 (19) 108 (18) 103 (19) 72 (18)
RF+ polyarthritis 30 (3) 11 (3) 19 (3) 14 (2) 16 (4)
Enthesitis related 54 (6) 16 (4) 38 (6) 37 (7) 17 (4)
Psoriatic 67 (7) 28 (8) 39 (6) 40 (7) 27 (7)
Undifferentiated 66 (7) 25 (7) 41 (7) 34 (6) 32 (8)
Active joint count 2 (1–5) 2 (1–6) 2 (1–4) 0.12 2 (1–5) 2 (1–5) 0.79
Limited joint count 1 (1–3) 1 (1–4) 1 (1–3) 0.01 1 (1–4) 1 (1–3) 0.07
Physician global 2.9 (1.5–5) 3.3 (1.9–5.8) 2.5 (1.5–4.6) 0.0001 3 (1.8–5.4) 2.5 (1.4–4.6) 0.001
Parent global 2.1 (0.5–5) 2.3 (0.6–5) 1.9 (0.3–5) 0.18 2.1 (0.5–5) 2.1 (0.3–5) 0.73
ESR 20 (6–49) 21 (7–50) 16 (5–49) 0.10 21 (7–50) 16 (5–49) 0.10
Pain (median, IQR) 30 (8–58) 33 (9–62) 27 (7–50) 0.07 30 (8–57) 30 (7–59) 0.7
CHAQ 0.6 (0.1–1.4) 0.8 (0.3–1.4) 0.6 (0.1–1.4) 0.06 0.6 (0.1–1.4) 0.6 (0.1–1.4) 0.36
Values are median (IQR) or number (%).
CHAQ, Childhood Health Assessment Questionnaire; ESR, erythrocyte sedimentation rate; ILAR, International League Against Rheumatism; RF, rheumatoid factor.
Table 2 Proportion of recorded values within individual components of JADAS at first visit to paediatric rheumatology
Component
Whole
cohort Systemic
Persistent
oligoarthritis
Extended
oligoarthritis
RF (−)
polyarthritis
RF (+)
polyarthritis
Enthesitis
related
Psoriatic
arthritis Undifferentiated
N 959 57 484 23 175 30 54 67 66
Active joint
count
959 (100) 57 (100) 484 (100) 23 (100) 175 (100) 30 (100) 54 (100) 67 (100) 66 (100)
Physician
global
794 (83) 42 (74) 412 (85) 23 (100) 142 (81) 21 (70) 48 (89) 57 (85) 49 (74)
Parent global 647 (68) 37 (65) 315 (65) 18 (78) 124 (71) 19 (63) 41 (76) 47 (70) 46 (70)
ESR 608 (64) 47 (82) 284 (59) 16 (70) 119 (68) 24 (80) 24 (54) 45 (67) 49 (74)
Values are number (%).
ESR, erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease Activity Score.
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JADAS3 results in the larger cohort were lower overall, but
showed a similar level of correlation across the study sample.
DISCUSSION
This paper describes JADAS across all ILAR categories of JIA
within a large ‘real-world’ dataset reﬂecting routine clinical care
and is the ﬁrst to place a benchmark of disease activity at initial
presentation to paediatric rheumatology in all ILAR categories.
The correlation between JADAS-71, JADAS-27 and JADAS-10
was excellent for all categories. Median JADAS-71 ranged from
7.5 to 20 and was signiﬁcantly higher among children with
polyarticular pattern disease or systemic onset JIA. The correl-
ation of JADAS-71 with individual markers of disease activity
was moderate to good for the whole cohort, with some vari-
ation between categories. The clinical applicability of
JADAS-71, JADAS-27 and JADAS-10 was limited by availability
of data.
We were unable to calculate a four-variable JADAS in the
majority of children in our cohort because of missing data.
Unlike a clinical trial, where a protocol would be strictly fol-
lowed to ensure that all data points are collected at each time
point, this observational study collected ‘real-world’ data as
recorded in the medical case notes. For many children, missing
data resulted from blood samples not being taken for ESR meas-
urement. To explore this, we tested the validity of excluding the
ESR from JADAS (labelled JADAS3-71, JADAS3-27 and
JADAS3-10). This increased the proportion of patients for
whom a score could be calculated from 37% to 58%. Further
validation of the JADAS3 in the cohort limited to those with
JADAS available, as well as in the larger cohort, resulting in a
more representative sample of our overall study cohort, found
similar results across the ILAR categories.
A large proportion of children had the physician global and
parent global assessments missing. Children with sufﬁcient data
available to calculate JADAS or JADAS3 had signiﬁcantly higher
physician global scores than those without. This implies that
physicians may be more likely to collect all data points in chil-
dren with more severe disease. One possible explanation is that
data may be collected more often if there is a perceived clinical
consequence—for example, access to biological medications.
The recently published Arthritis and Musculoskeletal Alliance
(ARMA)/British Society of Paediatric and Adolescent
Table 3 Correlation of JADAS and JADAS3 at first presentation to
paediatric rheumatology
Number
of
patients
JADAS-71
and
JADAS3-71
JADAS-27
and
JADAS3-27
JADAS-10
and
JADAS3-10
Whole cohort 352 0.96 0.96 0.96
Systemic onset 28 0.93 0.94 0.92
Persistent
oligoarthritis
164 0.96 0.96 0.96
Extended
oligoarthritis
13 0.94 0.91 0.95
RF− polyarthritis 67 0.93 0.93 0.89
RF+ polyarthritis 11 0.98 0.96 0.96
Enthesitis-related
arthritis
16 0.94 0.91 0.92
Psoriatic arthritis 28 0.95 0.95 0.94
Undifferentiated
arthritis
25 0.99 0.99 0.98
JADAS, Juvenile Arthritis Disease Activity Score; RF, rheumatoid factor.
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Rheumatology ‘Standards of Care for Children and Young
People with JIA’ stipulate that all children and young people
with JIA should have core outcome variables (including there-
fore the components of JADAS) measured at each review.10
Collection of these data as part of routine care is challenging,
but essential to ensure important targets of clinical remission are
achieved on and off medication.11
JADAS-71, JADAS-27 and JADAS-10 correlated highly across
all categories. Reduced joint count tools have not yet been vali-
dated in all ILAR categories, so this in itself is an interesting
ﬁnding.12 Since recording of active disease in every joint can be
technically difﬁcult and time-consuming, reduced joint counts
may potentially be useful in routine practice. The DAS28, a
28-joint reduced count, is an effective assessment of disease
activity in rheumatoid arthritis,13 14 although its use in adult
psoriatic arthritis has been criticised, with particular reference
to exclusion of the ankle and foot.15 Reduced joint counts have
been shown to correlate with whole joint counts in clinical trials
of patients with JIA, but have not been validated in the routine
clinical setting in all subtypes.12 Routine application of the
27-joint reduced joint count would improve the ease and speed
of examination, but has the potential to miss clinically relevant
information.
Correlation of JADAS-71 with individual markers of disease
activity was moderate to good for the whole cohort. These ﬁnd-
ings are similar to the results of previous validation
studies.4 5 16 This study demonstrated signiﬁcant variation
across the ILAR categories. For example, in children with oli-
goarticular JIA, the moderate correlation with AJC reﬂected a
limited range of active joints associated with a wide range of
global scores. Variation between the categories may reﬂect the
heterogeneity of the disease (particularly if extra-articular fea-
tures (enthesitis or rash) dominate the physician and parental
global scores) and may relate, in part, to the low numbers
within some categories.
Correlation of JADAS-71 with the ESR was moderate overall
(0.53), varying markedly between categories. Correlation was
moderate in children with systemic onset JIA (0.6), and moderate
to low in all other categories, except undifferentiated JIA, a
highly diverse and difﬁcult to interpret category of children.
Correlation of JADAS3-71 with the ESR was low in all ILAR
categories. This may relate in part to the fact that we allowed a
window of 30 days to collect the ESR at baseline, reﬂecting
current clinical practice. In the UK, blood samples are often not
checked at the ﬁrst visit, but are taken when the child returns
for treatment, such as a joint injection under general anaesthetic
or intravenous therapy. Therefore, it is possible that the result
may have been inﬂuenced on some occasions by treatment. The
infrequent use of oral steroids limits the likelihood of this
scenario.
Biomarkers are readily available, non-subjective assays, poten-
tially adding useful information to other more subjective but
more responsive disease activity surrogates.17 However, the ana-
lysis of a number of rheumatoid arthritis composite indices has
suggested that acute phase reactants provide little information
on actual disease activity on top of that provided by the combin-
ation of several clinical indices.18 Furthermore, it is likely that
biomarkers are less responsive to disease ﬂares in oligoarticular
disease than in polyarticular disease. Exclusion of the ESR
( JADAS3) did not reduce the correlation of JADAS with other
surrogates for disease activity. JADAS3 may therefore be a prag-
matic alternative to JADAS in the absence of an ESR measure-
ment in the clinical setting.
Baseline data were used in this study, as disease activity is
often the most severe at ﬁrst presentation. The use of baseline
data allowed this analysis to benchmark the severity of disease
at this time point, using baseline JADAS. However, even at this
point, the ESR was not measured in all children, reﬂecting
routine clinical practice in the UK. This resulted in a limited
number of children for whom JADAS could be calculated, par-
ticularly in some ILAR categories. The small population of chil-
dren with JADAS available represents a possible limitation of
this study, with respect to applying our results across the wider
JIA population.
A further limitation of our analysis may be the use of ILAR
category as assigned at the ﬁrst presentation. It has previously
Table 5 Correlation of JADAS-71 and JADAS3-71 with individual measures of disease activity in the 352 patients with JADAS available
Whole
cohort Systemic
Persistent
oliogarthritis
Extended
oligoarthritis
RF (−)
polyarthritis
RF (+)
polyarthritis
Enthesitis
related
Psoriatic
arthritis Undifferentiated
N 352 28 164 13 67 11 16 28 25
JADAS-71
AJC 0.75 0.79 0.47 0.8 0.73 0.95 0.78 0.82 0.85
Physician global 0.73 0.53 0.73 0.55 0.7 0.66 0.67 0.5 0.83
Parent global 0.57 0.62 0.71 0.75 0.33 0.39 0.68 0.39 0.65
ESR 0.53 0.6 0.33 0.01 0.48 0.4 0.43 0.41 0.69
LJC 0.51 0.71 0.34 0.49 0.29 0.76 0.67 0.61 0.47
Pain 0.48 0.37 0.58 0.57 0.34 0.04 0.81 0.47 0.54
CHAQ 0.58 0.46 0.57 0.71 0.44 0.54 0.71 0.6 0.63
JADAS3-71
AJC 0.79 0.86 0.53 0.88 0.83 0.95 0.82 0.79 0.87
Physician global 0.72 0.41 0.73 0.54 0.64 0.7 0.61 0.59 0.85
Parent global 0.60 0.72 0.75 0.68 0.34 0.38 0.81 0.4 0.64
ESR 0.33 0.36 0.1 −0.27 0.22 0.29 0.16 0.17 0.62
LJC 0.53 0.79 0.38 0.47 0.33 0.77 0.57 0.58 0.42
Pain 0.51 0.46 0.62 0.54 0.31 0.1 0.8 0.48 0.5
CHAQ 0.58 0.5 0.59 0.65 0.47 0.53 0.74 0.5 0.63
AJC, active joint count; CHAQ, Childhood Health Assessment Questionnaire; ESR, erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease Activity Score; LJC, limited joint
count; RF, rheumatoid factor.
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been noted that the ILAR category can change over time,9 par-
ticularly in children with oligoarticular pattern disease. Since
this was within the ﬁrst 6 months of disease for the majority of
children, the assigned ILAR category can only be considered a
‘predicted’ ILAR category, and further validation of the JADAS
and JADAS3 result at later time points is also required. The reli-
ability and sensitivity to change of JADAS3 could not be ascer-
tained in this cohort of children at ﬁrst presentation.
CONCLUSION
In conclusion, this study is the ﬁrst to apply JADAS to all ILAR
categories of JIA in the routine clinical setting at the time of
ﬁrst presentation, adding further information about the feasibil-
ity and construct validity of JADAS in the clinical setting. For
the majority of categories, clinical feasibility would be improved
by exclusion of the ESR, allowing a composite measure of
disease activity at the bedside. An amended score ( JADAS3),
which omits the ESR, correlates well with JADAS.
Routine collection of the core outcome variables would
permit calculation of JADAS3 at the bedside, offering the clin-
ical team an opportunity to improve the quality of clinical care
through a more precise, less subjective summary of disease activ-
ity, which can be more accurately compared with previous mea-
surements and clearly communicated to children and their
families.
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